UK Claims World First With ‘Point Of Care’ Manufacturing Rules
MHRA Says New Rules Will Increase Availability Of Innovative New Products
The MHRA says its proposals for a new, tailormade regulatory regime for personalized medicines manufactured at the point of care are evidence of its “intent to move away from a common perception of regulators as a progress blocker to a progress enabler.”
